9 completed, 4 unknown, 2 active not recruiting, 2 enrolling by invitation. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Completed 9, Unknown 4, Active not recruiting 2, Enrolling by invitation 2, Recruiting 1 |
Follow Pulmonary Eosinophilia: new trials by email Literature Review of Pulmonary Eosinophilia trials Research Report on Pulmonary Eosinophilia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| BenRalizumab Effect on Airway Remodeling in Severe asTHma Benralizumab 30 mg/ml - Asthma; Eosinophilic, Airway Remodeling | Phase 4 | Completed | Aristotle University Of Thessaloniki | 36 | 2024-03-01 | 2026-10-28 |
| A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps dupilumab, mepolizumab - Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic | Phase 4 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 220 | 2023-04-27 | 2025-07-01 |
| BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging Benralizumab - Asthma | Phase 4 | Completed | AstraZeneca | 45 | 2022-10-11 | 2025-03-25 |
| Predictive Signature of Benralizumab Response Benralizumab Prefilled Syringe - Asthma; Eosinophilic, Severe Asthma | Phase 4 | Recruiting | Nantes University Hospital | 220 | 2021-10-11 | 2024-04-26 |
| Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma Mepolizumab, Salbutamol - Asthma | Phase 4 | Completed | GlaxoSmithKline | 100 | 2021-06-29 | 2024-12-10 |
| Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma Reslizumab - Asthma; Eosinophilic | Phase 4 | Completed | McMaster University | 10 | 2021-02-10 | 2024-01-25 |
| A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Symbicort®, Fasenra®, Ventolin® - Asthma, Severe Eosinophilic Asthma | Phase 4 | Completed | AstraZeneca | 170 | 2020-07-27 | 2025-01-09 |
| Anti-viral Effects of Azithromycin in Patients With Asthma and COPD Azithromycin, Placebo oral tablet - Asthma, COPD | Phase 4 | Unknown | Bispebjerg Hospital | 100 | 2020-03-02 | 2021-07-26 |
| A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil Mepolizumab 100 MG [Nucala] - Eosinophilic Asthma | Phase 4 | Unknown | University of Sao Paulo General Hospital | 18 | 2020-01-09 | 2020-01-14 |
| Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Benralizumab, Placebo - Asthma | Phase 4 | Active not recruiting | AstraZeneca | 75 | 2019-10-08 | 2026-09-25 |
| Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab". Mepolizumab, Omalizumab - Asthma, Eosinophilic Asthma | Phase 4 | Unknown | University of Newcastle, Australia | 200 | 2018-11-03 | 2020-10-14 |
| Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma Prednisolone, Placebo oral capsule - Asthma | Phase 4 | Completed | NHS Greater Glasgow and Clyde | 33 | 2018-10-19 | 2020-03-06 |
| Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 4 | Unknown | University of Rostock | 20 | 2018-09-01 | 2018-08-29 |
| Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Mepolizumab 100mg SC, Albuterol/salbutamol MDIs, Omalizumab - Asthma | Phase 4 | Completed | GlaxoSmithKline | 145 | 2016-03-17 | 2019-08-19 |
| Small Particle Steroids in Refractory Asthma Ciclesonide, Placebo - Asthma | Phase 4 | Completed | University of Nottingham | 30 | 2010-01-01 | 2014-01-31 |
| The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia prednisolone 0.5 mg/kg/day for three months, prednisolone 0.5 mg/kg/day for six months - Eosinophilic Pneumonia, Chronic Disease | Phase 4 | Completed | Hamamatsu University | 50 | 2008-06-01 | 2014-09-19 |
Asthma (15) · Lung Diseases (3) · Airway Remodeling (1) · Bronchial Diseases (1) · Chronic Disease (1) · Churg-Strauss Syndrome (1) · Eosinophilia (1) · Immune System Diseases (1) · Inflammation (1) · Lung Diseases, Obstructive (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Tract Diseases (1) · Smoking (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Hypereosinophilic Syndrome (18) · Leukocyte Disorders (18) · Eosinophilia (17) · Respiratory Tract Diseases (17) · Hypersensitivity (15) · Hypersensitivity, Immediate (15) · Lung Diseases (15) · Respiratory Hypersensitivity (15) · Bronchial Diseases (14) · Immune System Diseases (14) · Lung Diseases, Obstructive (14) · Pathological Conditions, Signs and Symptoms (3) · Disease Attributes (2)
benralizumab (6) · mepolizumab (6) · Albuterol (3) · Omalizumab (2) · Prednisolone (2) · Azithromycin (1) · Biological Products (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Injections (1) · ciclesonide (1) · dupilumab (1) · reslizumab (1)
AstraZeneca (3) · GlaxoSmithKline (2) · Aristotle University Of Thessaloniki (1) · Azienda Ospedaliero Universitaria di Cagliari (1) · Bispebjerg Hospital (1) · Copenhagen University Hospital, Rigshospitalet (1) · Endeavor Health (1) · Hamamatsu University (1) · McMaster University (1) · NHS Greater Glasgow and Clyde (1) · Nantes University Hospital (1) · University of Newcastle, Australia (1) · University of Nottingham (1) · University of Rostock (1) · University of Sao Paulo General Hospital (1)
United Kingdom (5) · France (4) · United States (4) · Canada (3) · Denmark (3) · Germany (3) · Australia (2) · Belgium (2) · Italy (2) · Spain (2) · Sweden (2) · Argentina (1) · Brazil (1) · Greece (1) · India (1)
Celeste Porsbjerg, MD, PhD (1) · Christian Pedersen, MD (1) · Christian von Buchwald (1) · Dr. David Jackson (1) · Giselle Mosnaim, MD, MS (1) · Ian Pavord (1) · Kalliopi Domvri, Dr (1) · Kingo Chida, MD, PhD (1) · Marek Lommatzsch, MD (1) · Mario Castro, MD (1) · Parameswaran Nair, MD, PhD (1) · Peter Wark, MBBS/PhD (1) · Rekha Chaudhuri, MD (1) · Rodrigo A Athanazio, MD, PhD (1)
PMID 12045120, PMID 21037369, PMID 25614171, PMID 25858909, PMID 28461289, PMID 29221581, PMID 31798645, PMID 32762056, PMID 33369570, PMID 33971856, PMID 37131265, PMID 37343842, PMID 38071986, PMID 42458446
2015 (1), 2018 (1), 2019 (1)